- Oral Abstract Session A: Cancers of the Esophagus and Stomach
- Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
- Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
Oral Abstract Session A: Cancers of the Esophagus and Stomach
Identification and characterization of recurrent neoantigens in upper gastrointestinal (GI) cancers.
Francesca Battaglin, Andrew Elliott, Jian Zhang, et al.
The study identified candidate recurrent peptides with high HLA-binding affinity and an association with a positive TIS signature in both MSI and MSS tumors. This points to the importance of recurrent neoantigens as potential cancer immunotherapy targets.
Jean-Philippe Metges, Ken Kato, Jong-Mu Sun, et al.
This study demonstrates: Pembrolizumab plus chemotherapy continued to show a significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy alone with a manageable safety profile. The study recommends first-line treatment with pembrolizumab plus chemotherapy as the new standard of care in untreated, advanced esophageal and EGJ cancer. More info at NCT03189719.
Kohei Shitara, Yelena Y. Janjigian, Markus H. Moehler, et al.
The continued clinically meaningful efficacy and acceptable safety profile support the use of nivolumab plus chemotherapy as standard first-line therapy in previously untreated patients with advanced advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC). More info at: NCT02872116.
Ken Kato, Yoshinori Ito, Hiroyuki Daiko, et al.
Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) improved overall survival over cisplatin and 5-fluorouracil for locally advanced esophageal cell squamous carcinoma. The toxicity profile proved to be manageable. For the study authors, DCF means the new standard for the neoadjuvant treatment of ESCC.
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Zhenwei Peng, Wenzhe Fan, Bowen Zhu, Jiaping Li, Ming Kuang
Lenvatinib along with transarterial chemoembolization may improve clinical outcomes. For the study authors, this could be the new first-line treatment for advanced hepatocellular carcinoma. More info: NCT03905967.
Do-Youn Oh, Aiwu Ruth He, Shukui Qin, et al.
The study results with a significantly better overall survival and disease-free survival indicate that durvalumab + gemcitabine/cisplatin could be a new first-line standard of care for advanced biliary tract cancer. More info: NCT03875235.
Ghassan K. Abou-Alfa, Stephen Lam Chan, Masatoshi Kudo, et al.
Durvalumab was non-inferior to sorafenib. The safety of the treatment is rated as favorable by the authors. The combination of a single initial dose of tremelimumab(T) plus durvalumab (D) in Single T Regular Interval D (STRIDE) resulted in superior efficacy compared to sorafenib. The authors assess the risk-benefit profile as favorable and recommend STRIDE as a new systemic first-line therapy standard for unresectable hepatocellular carcinoma (uHCC). More info: NCT03298451.
Pascal Hammel, Iman El-Hariry, Teresa Macarulla, et al.
The addition of eryaspase demonstrated a well-tolerated profile and an encouraging survival benefit in the irinotecan/5FU subgroup, but the primary endpoint of improved overall survival was missed. More info: NCT03665441.
More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus
Claire Gallois, Qian Shi, Jeffrey P. Meyers, et al.
Oxaliplatin-based adjuvant chemotherapy for six months in stage III colon cancer resulted in a decrease in disease-free and overall survival when treatment was stopped early. Discontinuation of oxaliplatin early did not result in significantly worse outcomes. If significant neurotoxicity occurs during a 6-month program, the available data advise against continuing oxaliplatin beyond 75% of planned cycles of adjuvant chemotherapy. The study continues to favor fluoropyrimidines as the cornerstone of adjuvant chemotherapy for localized colon cancer.
Heinz-Josef Lenz, Aparna Raj Parikh, David R. Spigel, et al.
Despite not meeting the primary endpoint of progression-free survival (PFS), NIVOLUMAB plus standard of care showed higher PFS rates after 12 months with acceptable safety. A higher response rate and more durable responses compared to standard of care in first-line metastatic colorectal cancer were also observed. More info: NCT03414983.
Tetsuya Hamaguchi, Atsuo Takashima, Junki Mizusawa, et al.
With or without the addition of oxaliplatin, there is no difference in survival benefit. OX is not recommended as initial therapy for elderly patients with metastatic colorectal cancer. More information: UMIN000008866.
Masahito Kotaka, Hiromichi Shirasu, Jun Watanabe, et al.
The authors note the association between ctDNA dynamics and improved clinical outcomes in MRD-positive patients: Stratification of postoperative treatment decisions using the assay is able to identify patients who are likely to benefit from adjuvant chemotherapy at all stages, including pStage II. More information: jRCT1031200006.
To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.